Vaxart, Inc. announced its financial results for the year ended December 31, 2025, reporting a revenue of $237.3 million, significantly up from $28.7 million in 2024. The company highlighted advancements in its COVID-19 and norovirus vaccine programs, with key data expected in 2026.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.